⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25322013 | 0.78 | — | — | |
| SCHEMBL2945619 | 0.75 | — | — | |
| SCHEMBL892378 | 0.75 | — | — | |
| SCHEMBL6057948 | 0.74 | — | — | |
| SCHEMBL3921767 | 0.73 | — | — | |
| SCHEMBL8058213 | 0.72 | LMNA (0.32) | — | |
| SCHEMBL6419847 | 0.72 | — | — | |
| SCHEMBL11577120 | 0.71 | — | — | |
| SCHEMBL452396 | 0.71 | — | — | |
| SCHEMBL3891567 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376443-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250368604-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250289794-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2025-09-18 | — | — | US | disclosed |
| US-12286413-B2 | Compounds and methods for treating cancer | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2025-04-29 | — | — | US | disclosed |
| US-20250129020-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-04-24 | — | — | US | disclosed |
| US-20250051258-A1 | PRODUCTION METHOD OF ASYMMETRIC CHAIN CARBONATE | DAIKIN INDUSTRIES, LTD. (JP) | 2025-02-13 | — | — | US | disclosed |
| CN-119350433-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2025-01-24 | — | — | CN | disclosed |
| US-12195427-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2025-01-14 | — | — | US | disclosed |
| US-12162832-B2 | Production method of asymmetric chain carbonate | DAIKIN INDUSTRIES, LTD. (JP) | 2024-12-10 | — | — | US | disclosed |
| CN-112867706-B | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-11-15 | — | — | CN | disclosed |
| US-8828667-B2 | Methods and compositions relating to isocyanate conjugates | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-09-09 | — | — | US | disclosed |
| US-20140200197-A1 | HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-07-17 | — | — | US | disclosed |
| WO-2014043019-A1 | HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-03-20 | — | — | WO | disclosed |
| WO-2013093931-A2 | NOVEL PRODRUGS OF PHENOLIC DRUGS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2013-06-27 | — | — | WO | disclosed |
| US-20100099201-A1 | METHODS AND COMPOSITIONS RELATING TO ISOCYANATE CONJUGATES | THE GOVERNMENT OF THE US, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-04-22 | — | — | US | disclosed |
| US-5935976-A | Antiviral ethers of aspartate protease substrate isosteres | NOVARTIS CORPORATION (US) | 1999-08-10 | — | — | US | disclosed |
| US-5807891-A | RETROVIRUSES | NOVARTIS AG (CH) | 1998-09-15 | — | — | US | disclosed |
| US-5663200-A | CARBAMOYL PEPTIDE DERIVATIVES AS VIRICIDES | CIBA-GEIGY CORPORATION (US) | 1997-09-02 | — | — | US | disclosed |
| EP-0708085-A2 | Antiviral ethers of aspartate protease substrate isosteres | CIBA-GEIGY AG (CH) | 1996-04-24 | — | — | EP | disclosed |
| US-4201783-A | Antidepressant substituted hexahydro benzopyrano [3,2-c] pyridines | LIPHA LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1980-05-06 | — | — | US | disclosed |